252 related articles for article (PubMed ID: 33244278)
1. The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma.
Jayanetti V; Sandhu S; Lusthaus JA
J Exp Pharmacol; 2020; 12():539-548. PubMed ID: 33244278
[TBL] [Abstract][Full Text] [Related]
2. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.
Lusthaus JA; Goldberg I
Expert Opin Investig Drugs; 2016 Oct; 25(10):1201-8. PubMed ID: 27548834
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
Tanna AP; Lin AB
Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for the treatment of glaucoma: a review of phase II & III trials.
Kaplan TM; Sit AJ
Expert Opin Emerg Drugs; 2022 Sep; 27(3):321-331. PubMed ID: 35924872
[TBL] [Abstract][Full Text] [Related]
5. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension.
Holló G; Bozkurt B; Irkec M
Expert Opin Pharmacother; 2009 Aug; 10(12):2015-24. PubMed ID: 19618994
[TBL] [Abstract][Full Text] [Related]
6. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
7. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
Holló G; Topouzis F; Fechtner RD
Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
[TBL] [Abstract][Full Text] [Related]
8. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO
Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574
[TBL] [Abstract][Full Text] [Related]
9. Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.
Crooke A; Colligris B; Pintor J
Curr Med Chem; 2012; 19(21):3508-22. PubMed ID: 22709004
[TBL] [Abstract][Full Text] [Related]
10. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.
Shih GC; Calkins DJ
Expert Rev Ophthalmol; 2012 Apr; 7(2):161-175. PubMed ID: 22737176
[TBL] [Abstract][Full Text] [Related]
11. New pharmacotherapy for the treatment of glaucoma.
Schehlein EM; Novack G; Robin AL
Expert Opin Pharmacother; 2017 Dec; 18(18):1939-1946. PubMed ID: 29172818
[TBL] [Abstract][Full Text] [Related]
12. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
13. Management of glaucoma: focus on pharmacological therapy.
Marquis RE; Whitson JT
Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
[TBL] [Abstract][Full Text] [Related]
14. Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs.
Lee SS; Robinson MR; Weinreb RN
J Glaucoma; 2019 Sep; 28(9):846-857. PubMed ID: 31261285
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of prostaglandin analogues in glaucoma.
Lindén C
Expert Opin Investig Drugs; 2001 Apr; 10(4):679-94. PubMed ID: 11281818
[TBL] [Abstract][Full Text] [Related]
16. Glaucoma Drugs in the Pipeline.
Kaufman PL; Mohr ME; Riccomini SP; Rasmussen CA
Asia Pac J Ophthalmol (Phila); 2018; 7(5):345-351. PubMed ID: 30221499
[TBL] [Abstract][Full Text] [Related]
17. Current opinion in ophthalmology: novel glaucoma devices in the pipeline.
Ittoop SM; Seibold LK; Kahook MY
Curr Opin Ophthalmol; 2019 Mar; 30(2):117-124. PubMed ID: 30575619
[TBL] [Abstract][Full Text] [Related]
18. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
19. Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice.
Millar JC; Savinainen A; Josiah S; Pang IH
Exp Eye Res; 2019 Nov; 188():107763. PubMed ID: 31421135
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
